30 Day Trial


Founded in 1992, ORTHOWORLD® is the only provider of strategic intelligence in the world solely focused on the global orthopaedic market. Its singular mission is helping orthopaedic companies and individuals improve their performance.

Highly specialized product offerings such as ORTHOWORLD Membership, ORTHOFLASH®, market reports, BONEZONE® and OMTEC® empower industry participants to respond to challenges, maximize opportunities and more aggressively expand their orthopaedic businesses. We welcome the opportunity to assist you.


  • 10:30 a.m. Medtronic gained FDA 510(k) clearance for Kyphon™ HV-R Bone Cement for use in sacroplasty.
  • Study results indicate that NuVasive's porous PEEK technology, used in the Cohere® cervical interbody fusion device, presents a clinically viable option to improve osseointegration and fusion.
  • In the Phase III 16-02 clinical trial of Anika Therapeutics' CINGAL, statistically significant results in pain reduction were not demonstrated at the primary endpoint of 26 weeks.
Read More

Articles of Interest All Articles

Robotics in Orthopaedic Surgery: Answers to Three Questions

A detailed look at the robotic technology players and their products, as well as how they fit into the greater industry context of data, outcomes and adoption.